Abstract 505P
Background
The RATIONALE-312 study reports PD-1 inhibitor (tislelizumab) plus platinum–etoposide could improve survival of patients with extensive-stage small-cell lung cancer (SCLC). Based on this, we initiated a pilot study to explore the safety and feasibility of neoadjuvant Tislelizumab plus platinum–etoposide in limited-stage SCLC.
Methods
Treatment-naïve limited-stage SCLC patients with ECOG PS 0-1 status were enrolled. Patients received 4 cycles of Tislelizumab (200mg, q3w) plus platinum (Cisplatin 75 mg/m2 or Carboplatin AUC5) – etoposide (100 mg/m2). The feasibility of surgery was then reassessed by radiology. Candidates for complete resection underwent surgery; otherwise, they received radiotherapy. Patients who received surgery also received adjuvant Tislelizumab plus platinum–etoposide therapy for 4 cycles. Primary endpoints were safety and feasibility. Secondary endpoints were objective response rate (ORR), pathologic response, and survival.
Results
A total of 8 eligible patients were enrolled up to April 2023. The median age was 65 (range: 57-70) with 6 male patients and 7 smokers. Among them, 1, 4, and 3 patients had stage ⅡB, ⅢA and ⅢB disease, respectively. No previously unreported toxic effects were observed. Treatment-related adverse events (TRAEs) of any grade occurred in 7 of 8 (87.5%) patients. Grade 3-4 events occurred in 6 of 8 (75%) patients. There were no severe adverse events. The majority of TRAEs was chemotherapy-related, and 2 patients suffered mild immune-related thyroid dysfunction. Seven patients completed 4 cycles of neoadjuvant therapy, and the best ORR was 85.7% (5 partial response and 1 stable disease). Of the 7 patients, 5 were assessed to be resectable. There were no treatment-related surgical delays. R0 resection and pathological downstaging were achieved for all 5 patients (100%) without any serious surgical complications. At a median of 18 months (range: 10 - 20) of follow-up, all patients were alive, and all the patients who received surgery were recurrence-free.
Conclusions
Neoadjuvant Tislelizumab plus platinum–etoposide was associated with tolerable side effects and was effective for patients with limited-stage SCLC.
Clinical trial identification
NCT04542369.
Editorial acknowledgement
Legal entity responsible for the study
Shanghai Pulmonary Hospital.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
270P - Germline BRCA1/2 pathogenic variants in Japanese patients with prostate cancer are predictive factors for androgen receptor-axis-targeted therapy or chemotherapy for castration-resistant prostate cancer
Presenter: Shigekatsu Maekawa
Session: Poster Display
Resources:
Abstract
271P - Prostate cancer with histone modifier UTX mutations can benefit from olaparib
Presenter: NOBUHITO MURAMOTO
Session: Poster Display
Resources:
Abstract
272P - Comparison between MRI-targeted and standard biopsy for prostate cancer detection: A systematic review and meta-analysis
Presenter: Andree Kurniawan
Session: Poster Display
Resources:
Abstract
273P - The diagnostic performance of cognitive MRI-targeted biopsy in biopsy-naïve patients undergoing systematic 14-region 18-core biopsy: Do the three areas affect the results?
Presenter: Yuka Toyama
Session: Poster Display
Resources:
Abstract
274P - Index tumor location influencing early biochemical recurrence after radical prostatectomy in patients with negative surgical margins
Presenter: Jun Akatsuka
Session: Poster Display
Resources:
Abstract
275P - Prognosis of metastatic castration-resistant prostate cancer in response to chemotherapy and PSMA expression in circulating tumor cells
Presenter: Naoya Nagaya
Session: Poster Display
Resources:
Abstract
276P - Prognostic significance of p53 mutation in metastatic hormone-sensitive prostate cancer
Presenter: Lakshmi Kamala
Session: Poster Display
Resources:
Abstract
277P - Vasohibin-1 expression as a biomarker of aggressive growth in prostate ductal adenocarcinoma
Presenter: Murad Salomov
Session: Poster Display
Resources:
Abstract
278P - Full-coverage radiotherapy for prostate cancer patients with oligometastases
Presenter: Bichun Xu
Session: Poster Display
Resources:
Abstract
279P - Hypofractionated radiotherapy protocol implementation and early outcomes for prostate cancer patients: A single institution retrospective review
Presenter: Thu Nguyen
Session: Poster Display
Resources:
Abstract